RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give
higher doses of chemotherapy and kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy followed by
peripheral stem cell transplantation or bone marrow transplantation in treating patients who
have relapsed or recurrent germ cell cancer.
OBJECTIVES: I. Determine the response rate, overall survival, and disease-free survival of
patients with refractory or relapsed germ cell carcinoma treated with high-dose induction
chemotherapy comprising carboplatin and etoposide followed by autologous bone marrow or
peripheral blood stem cell rescue.
OUTLINE: Autologous peripheral blood stem cells (PBSC) or bone marrow is harvested. Patients
receive carboplatin IV continuously and etoposide IV over 1 hour on days -5 through -3.
Autologous PBSC or bone marrow is reinfused on day 0.
PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study.
DISEASE CHARACTERISTICS: Documented relapsed or refractory germ cell cancer of the
following sites of origin: Testes Ovary Retroperitoneum Mediastinum Other sites Any stage
of disease allowed Any histologic subtype allowed Seminoma only allowed if ineligible for
radiotherapy Failed to achieve complete remission (CR) following at least 3 courses of a
standard platinum-containing regimen or experienced clear relapse following CR obtained
with such a regimen Absence of tumor markers in the presence of stable residual masses
after initial treatment may be allowed (surgical biopsy should be performed; if medically
safe, to confirm persistence of disease and rule out mature teratoma or fibrosis) Prior
CNS involvement allowed in the absence of gross residual CNS tumor following definitive
local therapy (surgery plus radiotherapy) No gross tumor involvement on bone marrow biopsy
PATIENT CHARACTERISTICS: Age: 15 to 60 Performance status: Karnofsky 80-100%
Hematopoietic: Granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3
Hepatic: Bilirubin less than 2.0 mg/dL SGOT/SGPT less than 2 times normal Albumin greater
than 3.0 mg/dL Renal: Creatinine less than 1.8 mg/dL Cardiovascular: LVEF at least 50% No
other serious cardiac disease that would preclude transplantation Pulmonary: DLCO, FEV1,
and FVC at least 50% predicted pO2 at least 70 mm Hg on room air Other: HIV negative No
other concurrent serious psychiatric, neurologic, neoplastic, immunologic, or other
medical problem that would preclude transplantation Not pregnant
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
Characteristics Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics
No prior chest irradiation Surgery: See Disease Characteristics